TAP is revising its 60-second "Heartbreak Hotel" ad in response to FDA objections. A March 15 letter from the ad division maintains that the ad did not sufficiently present the limitations to the indication for Prevacid or the side effect information. TAP has resolved the issue with the agency and a corrected version of the ad will run shortly, the Takeda/Abbott joint venture said
You may also be interested in...
TAP has revised its TV ad for Prevacid by increasing the prominence of the drug's indication in response to a letter from FDA's ad division
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011